• Regulatory
Read PDF

A1M Pharma announced today that Nasdaq Stockholm AB has decided that its share will be given observation status. The company yesterday published its interim report for the third quarter of 2018 with information on its financial situation. The current rules of First North state that a listed company can be given observation status if any circumstance exists that results in material adverse uncertainty in respect of the company’s financial situation. As previously announced, the Board of Directors of A1M Pharma works to ensure its financing needs. The company is currently engaged in a capital raising process, supported by a financial advisor.

– A1M Pharma is in a process to secure the company's continued funding and expects to be able to present a solution to strengthen its working capital in the coming weeks, says Tomas Eriksson, CEO, A1M Pharma.

For more information, please contact:
Tomas Eriksson, CEO
Telephone: +46 46-286 50 30
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

About A1M Pharma
Several preclincal studies indicate that A1M Pharma´s candidate drug ROSgard™ based on endogenous protein Alpha 1 Microglobulin – restores impairments to kidney function by repairing damaged tissues and protecting against oxidative stress. A1M Pharma is listed on Nasdaq First North Stockholm. A1M Pharma´s Certified at Nasdaq First North is Erik Penser Bank AB, +46 8 463 80 00.
A1M Pharma AB | Scheelevägen 22 | 223 63 Lund
+46 46 286 50 30 | info@a1m.se
Member of Preeclampsia Foundation
Legal disclaimer | © Copyright - A1M